SML1938
LY450139
≥98% (HPLC)
Synonym(s):
(2S)-2-Hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide, LY 450139, LY-450139, Semagacestat
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H27N3O4
CAS Number:
Molecular Weight:
361.44
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C([C@@H](NC([C@@H](O)C(C)C)=O)C)N[C@@H](C1=CC=CC=C1CCN2C)C2=O
InChI
1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1
InChI key
PKXWXXPNHIWQHW-RCBQFDQVSA-N
Biochem/physiol Actions
LY450139 (Semagacestat) is a notch-sparing, potent and selective gamma-secretase inhibitor. LY450139 lowers plasma and cerebrospinal fluid Aβ in humans.
Notch-sparing, potent and selective gamma-secretase inhibitor and inverse modulator of Aβ
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Vito Antonio Baldassarro et al.
Disease models & mechanisms, 10(5), 671-678 (2017-02-27)
Microvascular dysfunction is considered an integral part of Alzheimer disease (AD) pathogenesis, but the possible relationship between amyloid pathology, microvascular dysfunction and cell death is still unclear. In order to investigate the influence of intraneuronal amyloid-β (Aβ) accumulation on vulnerability
Jonathan D Best et al.
The Journal of pharmacology and experimental therapeutics, 313(2), 902-908 (2005-03-04)
The efficacy of gamma-secretase inhibitors in vivo has, to date, been generally assessed in transgenic mouse models expressing increased levels of amyloid-beta (Abeta) peptide thereby allowing the detection of changes in Abeta production. However, it is not clear whether the
Julie Colin et al.
Journal of Alzheimer's disease : JAD, 52(3), 975-987 (2016-05-11)
Oligomeric amyloid-β (Aβ) peptide contributes to impaired synaptic connections and neurodegenerative processes, and as such, represents a primary therapeutic target for Alzheimer's disease (AD)-modifying approaches. However, the lack of efficacy of drugs that inhibit production of Aβ demonstrates the need
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML1938-25MG | 04061832983820 |
| SML1938-5MG | 04061832983837 |